The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

Blood

Volumn 102, Issue 7, 2003, Pages 2562-2567

  Fonseca, Rafael ^a   Debes Marun, Carina S ^b   Picken, Elisa B ^b   Dewald, Gordon W ^b   Bryant, Sandra C ^b   Winkler, Jerry M ^b   Blood, Emily ^b   Oken, Martin M ^b   Santana Dávila, Rafael ^b   González Paz, Natalia ^b   Kyle, Robert A ^b   Gertz, Morie A ^b   Dispenzieri, Angela ^b   Lacy, Martha Q ^b   Greipp, Philip R ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ANEUPLOIDY; ARTICLE; CHROMOSOME 13; CHROMOSOME ABERRATION; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION; DIPLOIDY; DNA CONTENT; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPODIPLOID; IMMUNOGLOBULIN H TRANSLOCATION; INTERPHASE; KARYOTYPE; MAJOR CLINICAL STUDY; METAPHASE; MONOSOMY; MULTIPLE MYELOMA; NONHYPERDIPLOID VARIANT MULTIPLE MYELOMA; PLOIDY; PRIORITY JOURNAL; TETRAPLOIDY;

EID: 0141481984     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-02-0493     Document Type: Article

References (43)

1. Fonseca R, Dewald G, Coignet L. Cytogenetic abnormalities in multiple myeloma. Hematol Oncol Clin North Am. 1999;13:1169-1180.
2. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
3. Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol. 2001;112:167-174.
4. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66:380-390.
5. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12:960-969.
6. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229-2238.
7. Debes-Marun C, Dewald G, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17:427-436.
8. Barlogie B, Johnston DA, Smallwood L, et al. Prognostic implications of ploidy and proliferative activity in human solid tumors. Cancer Genet Cytogenet. 1982;6:17-28.
9. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood. 1985;66:338-341.
10. Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041-1047.
11. Spurbeck JL, Carlson RO, Allen JE, Dewald GW. Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts and solid tumors with in situ techniques. Cancer Genet Cytogenet. 1988;32:59-66.
12. Oken MM, Leong T, Lenhard RE Jr, et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer. 1999;86:957-968.
13. Fonseca R, Oken M, Greipp P. The t(4;14)(p16.3; q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance. Blood. 2001;98:1271-1272.
14. Fonseca R, Harrington D, Oken M, et al. Myeloma and the t(11;14)(q13;q32) represents a uniquely defined biological subset of patients. Blood. 2002;99:3735-3741.
15. Fonseca R, Harrington D, Oken M, et al. Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (delta 13) in multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study. Cancer Res. 2002;62:715-720.
16. Fonseca R, Oken M, Harrington D, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia. 2001;15:981-986.
17. Fonseca R, Blood E, Rue M, et al. clinical and biologic implications of recurrent genomic abnormalities in myeloma. Blood. 2003;101:4569-4575.
18. Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998;101:7-11.
19. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417-1424.
20. Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001;98:2266-2268.
21. Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell. 1999;3:119-123.
22. Greipp PR, Trendle MC, Leong T, et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma. 1999;35:83-89.
23. Fonseca R, Harrington D, Blood E, et al. Amolecular classification of multiple myeloma (MM) based on cytogenetic abnormalities detected by interphase FISH, is powerful in identifying discrete groups of patients with dissimilar prognosis [abstract]. Blood. 2001;98:733a.
24. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579-1583.
25. Calasanz MJ, Cigudosa JC, Odero MD, et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol. 1997;98:418-425.
26. Heerema NA, Nachman JB, Sather HN, et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999;94:4036-4045.
27. Rubio Bueno P, Naval Gias L, Garcia Delgado R, Domingo Cebollada J, Diaz Gonzalez FJ. Tumor DNA content as a prognostic indicator in squamous cell carcinoma of the oral cavity and tongue base. Head Neck. 1998;20:232-239.
28. Pujol JL, Simony J, Jolimoy G, et al. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer. 1996;74:964-970.
29. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol. 1995;90:106-112.
30. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311:231-235.
31. Pappo AS, Crist WM, Kuttesch J, et al. Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 1993;11:1901-1905.
32. Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol. 2000;37:381-395.
33. Yeoh E, Ross M, Shurtleff S, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133-143.
34. Fonseca R, Witzig TE, Gertz MA, et al. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol. 1998;101:296-301.
35. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674-681.
36. Uchida T, Kinoshita T, Ohno T, Ohashi H, Nagai H, Saito H. Hypermethylation of p16 INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia. 2001;15:157-165.
37. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
38. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611-5622.
39. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97:822-825.
40. Gutierrez NC, Hernandez JM, Garcia JL, et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia. 2001;15:840-845.
41. Taniwaki M, Nishida K, Ueda Y, Takashima T. Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Leuk Lymphoma. 1996;21:25-30.
42. Perez Losada A, Woessner S, Sole F, Florensa L, Bonet C. Chromosomal and in vitro culture studies in a case of primary plasma cell leukemia. Cancer Genet Cytogenet. 1994;76:36-38.
43. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037.